JOURNAL BROWSE
Search
Advanced SearchSearch Tips
TM-25659-Induced Activation of FGF21 Level Decreases Insulin Resistance and Inflammation in Skeletal Muscle via GCN2 Pathways
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Molecules and Cells
  • Volume 38, Issue 12,  2015, pp.1037-1043
  • Publisher : Korea Society for Molecular and Cellular Biology
  • DOI : 10.14348/molcells.2015.0100
 Title & Authors
TM-25659-Induced Activation of FGF21 Level Decreases Insulin Resistance and Inflammation in Skeletal Muscle via GCN2 Pathways
Jung, Jong Gab; Yi, Sang-A; Choi, Sung-E; Kang, Yup; Kim, Tae Ho; Jeon, Ja Young; Bae, Myung Ae; Ahn, Jin Hee; Jeong, Hana; Hwang, Eun Sook; Lee, Kwan-Woo;
  PDF(new window)
 Abstract
The TAZ activator 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H-imidazo[4,5-b]pyridine] (TM-25659) inhibits adipocyte differentiation by interacting with peroxisome proliferator-activated receptor gamma. 1 TM-25659 was previously shown to decrease weight gain in a high fat (HF) diet-induced obesity (DIO) mouse model. However, the fundamental mechanisms underlying the effects of TM-25659 remain unknown. Therefore, we investigated the effects of TM-25659 on skeletal muscle functions in C2 myotubes and C57BL/6J mice. We studied the molecular mechanisms underlying the contribution of TM-25659 to palmitate (PA)-induced insulin resistance in C2 myotubes. TM-25659 improved PA-induced insulin resistance and inflammation in C2 myotubes. In addition, TM-25659 increased FGF21 mRNA expression, protein levels, and FGF21 secretion in C2 myotubes via activation of GCN2 pathways (GCN2--ATF4 and FGF21). This beneficial effect of TM-25659 was diminished by FGF21 siRNA. C57BL/6J mice were fed a HF diet for 30 weeks. The HF-diet group was randomly divided into two groups for the next 14 days: the HF-diet and HF-diet + TM-25659 groups. The HF diet + TM-25659-treated mice showed improvements in their fasting blood glucose levels, insulin sensitivity, insulin-stimulated Akt phosphorylation, and inflammation, but neither body weight nor food intake was affected. The HF diet + TM-25659-treated mice also exhibited increased expression of both FGF21 mRNA and protein. These data indicate that TM-25659 may be beneficial for treating insulin resistance by inducing FGF21 in models of PA-induced insulin resistance and HF diet-induced insulin resistance.
 Keywords
FGF21;GCN2;inflammation;insulin resistance;TM-25659;
 Language
English
 Cited by
1.
FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadiponectinaemia: The BCAMS Study, Diabetes & Metabolism, 2017, 43, 3, 253  crossref(new windwow)
 References
1.
Anthony, T.G., McDaniel, B.J., Byerley, R.L., McGrath, B.C., Cavener, D.R., McNurlan, M.A., and Wek, R.C. (2004). Preservation of liver protein synthesis during dietary leucine deprivation occurs at the expense of skeletal muscle mass in mice deleted for eIF2kinase GCN2. J. Biol. Chem. 279, 36553-36561. crossref(new window)

2.
Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. (2007) Hepatic fibroblast growth factor 21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437. crossref(new window)

3.
De Sousa-Coelho, A.L., Relat, J., Hondares, E., Perez-Marti, A., Ribas, F., Villarroya, F., Marrero, P.F., and Haro, D. (2013). FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54, 1786-1797. crossref(new window)

4.
Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier, J.S., and Maratos-Flier, E. (2010). Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789. crossref(new window)

5.
Ge, X., Wang, Y., Lam, K.S., and Xu, A. (2012). Metabolic actions of FGF21: molecular mechanisms and therapeutic implications. Acta Pharmaceutica Sinica B. 2, 350-357. crossref(new window)

6.
Guo, F., and Cavener, D.R. (2007). The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metabol. 5, 1-12. crossref(new window)

7.
Hong, J.H., Hwang, E.S., McManus, M.T., Amsterdam, A., Tian, Y., Kalmukova, R., Mueller, E., Benjamin, T., Spiegelman, B.M., Sharp, P.A., et al. (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309, 1074-1078. crossref(new window)

8.
Huh J.Y., Park Y.J., Ham M., and Kim J.B. (2014) Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol. Cells 37, 365-371. crossref(new window)

9.
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007). Endocrine regulation of the fasting response by PPAR alpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425. crossref(new window)

10.
Jang, E.J., Jeong, H., Kang, J.O., Kim, N.J., Kim, M.S., Choi, S.H., Yoo, S.E., Hong, J.H., Bae, M.A., and Hwang, E.S. (2012). TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional coactivator TAZ. Br. J. Pharmacol. 165, 1584-1594. crossref(new window)

11.
Jung, J.G., Choi, S.E., Hwang, Y.J., Lee, S.A., Kim, E.K., Lee, M.S., Han, S.J., Kim, H.J., Kim, D.J., Kang, Y., et al. (2011). Supplementation of pyruvate prevents palmitate-induced impairment of glucose uptake in C2 myotubes. Mol. Cell Endocrinol. 345, 79-87. crossref(new window)

12.
Kanai, F., Marignani, P.A., Sarbassova, D., Yagi, R., Hall, R.A., Donowitz, M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L.C., et al. (2000). TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19, 6778-6791. crossref(new window)

13.
Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. (2005). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635. crossref(new window)

14.
Kim, K.H., Jeong, Y.T., Oh, H., Kim, S.H., Cho, J.M., Kim, Y.N., Kim, S.S., Kim, D.H., Hur, K.Y., Kim, H.K., et al. (2013). Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19, 83-92.

15.
Laeger, T., Henagan, T.M., Albarado, D.C., Redman, L.M., Bray, G.A., Noland, R.C., Munzberg, H., Hutson, S.M., Gettys, T.W., Schwartz, M.W., et al. (2014). FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913-3922. crossref(new window)

16.
Lees, E.K., Krol, E., Grant, L., Shearer, K., Wyse, C., Moncur, E., Bykowska, A.S., Mody, N., Gettys, T.W., and Delibegovic, M. (2014). Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell. 13, 817-827. crossref(new window)

17.
Lin, Z., Tian, H., Lam, K.S., Lin, S., Hoo, R.C., Konishi, M., Itoh, N., Wang, Y., Bornstein, S.R., Xu, A., et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 779-789. crossref(new window)

18.
Ota, T. (2013). Chemokine systems link obesity to insulin resistance. Diabetes Metab. J. 37, 165-172. crossref(new window)

19.
Park, S., Sadanala K.C., and Kim E.K. (2015). A metabolomic approach to understanding the metabolic link between obesity and diabetes. Mol. Cells 38, 587-596 crossref(new window)

20.
Wang, W.F., Li, S.M., Ren, G.P., Zheng, W., Lu, Y.J., Yu, Y.H., Xu, W.J., Li, T.H., Zhou, L.H., Liu, Y., et al. (2015) Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine 49, 119-129. crossref(new window)

21.
Wilson, G.J., Bunpo, P., Cundiff, J.K., Wek, R.C., and Anthony, T.G. (2013). The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J. Physiol. Endocrinol. Metab. 305, 1124-1133. crossref(new window)

22.
Woo, Y.C., Xu, A., Wang, Y., and Lam, K.S. (2013). Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. 78, 489-496. crossref(new window)

23.
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S, Tartaglia, L.A., et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830. crossref(new window)

24.
Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in dietinduced obese mice. Diabetes 58, 250-259. crossref(new window)